PRESS-RELEASE ·Filed Mar 19, 2026
Press release: earnings
Actionable Insight • Neutral
Traders should await the March 26 earnings release for material financial data. This announcement alone does not provide any actionable fundamentals but confirms timing for an upcoming catalyst.
Final — all horizons settled through T+60d
QNRX ▼ -43.70% at T+60d
NEUTRAL call ✗ call lost -43.70% · α vs SPY -58.05% · entry $8.26 → $4.65
T+1d
-3.86%
call -3.86% · α -2.12%
$7.94
settled 7mo ago
T+5d
-8.41%
call -8.41% · α -6.20%
$7.57
settled 7mo ago
T+20d
-21.79%
call -21.79% · α -29.41%
$6.46
settled 6mo ago
T+60d
-43.70%
call -43.70% · α -58.05%
$4.65
settled 4mo ago
Price Chart
Loading chart...
Executive Summary
Quoin Pharmaceuticals announced it will release its Q4 and full-year 2025 financial results and provide a corporate update on March 26, 2026. The press release contains no actual financial data, only an announcement of upcoming results and general company information.
Key Facts
- Quoin Pharmaceuticals will release Q4 and full-year 2025 financial results on March 26, 2026, before market open.
- The announcement includes a forward-looking corporate update with operational highlights and financial results.
- No financial figures (revenue, EPS, guidance) are disclosed in this press release.
- Company is focused on rare and orphan disease therapeutics with four products in development.
Financial Impact
None disclosed — actual financials to be reported on March 26, 2026
Risk Factors
- Lack of disclosed financials limits immediate trading relevance.
- Potential for negative reaction if upcoming results miss expectations, given small market cap ($85M).
Market Snapshot
Exchange
Nasdaq
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258994 |
14 reports for QNRX
50% Hit rate best @ T+5▲ +18.63%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 12, 2026 6d ago | ANALYST-UPGRADE | $4.36 $4.15 | ▼ −4.82% | ▼ −4.80% | $3.90 (−10.55%) |
Sep 2, 2026 6w ago | Insider Cluster | $6.74 $7.87 | ▲ +16.77% | ▲ +15.72% | $3.90 (−42.14%) |
Aug 28, 2026 7w ago | 8-K | $6.12 $6.22 | ▲ +1.63% | ▲ +1.93% | $3.90 (−36.27%) |
Aug 28, 2026 7w ago | Press Release | $6.12 $6.22 | ▼ −1.63% | ▼ −1.93% | $3.90 (+36.27%) |
Aug 28, 2026 7w ago | Press Release | $6.12 $6.22 | ▲ +1.63% | ▲ +1.93% | $3.90 (−36.27%) |
Aug 20, 2026 8w ago | 8-K | $5.57 $5.42 | ▼ −2.69% | ▼ −2.40% | $3.90 (−29.98%) |
Aug 7, 2026 10w ago | Press Release | $4.79 $5.36 | ▲ +11.90% | ▲ +11.93% | $3.90 (−18.58%) |
Jun 23, 2026 16w ago | 8-K | $3.83 $4.20 | ▲ +9.66% | ▲ +9.52% | $3.90 (+1.83%) |
May 7, 2026 23w ago | Press Release | $6.37 $5.93 | ▼ −6.91% | ▼ −7.74% | $3.90 (−38.78%) |
May 5, 2026 23w ago | ANALYST-UPGRADE | $6.31 $6.43 | ▲ +1.90% | ▲ +0.52% | $3.90 (−38.19%) |
Showing 10 of 14
US Market Status
Market Closed — Opens in 5h 48m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access